Variation in use of antipsychotic medications in nursing homes in the United States: A systematic review

BMC Geriatrics

Volumn 17, Issue 1, 2017, Pages

  Cioltan, Hannah ^a,b   Alshehri, Samah ^a   Howe, Carol ^c   Lee, Jeannie ^a,b   Fain, Mindy ^b   Eng, Howard ^a   Schachter, Kenneth ^a   Mohler, Jane ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Antipsychotics; Behavioral symptoms; Dementia; Nursing homes

Indexed keywords

NEUROLEPTIC AGENT;

AGED; CLINICAL PRACTICE; DEMENTIA; HOME FOR THE AGED; HUMAN; MEDICATION THERAPY MANAGEMENT; NURSING HOME; STANDARDS; STATISTICS AND NUMERICAL DATA; UNITED STATES;

AGED; ANTIPSYCHOTIC AGENTS; DEMENTIA; HOMES FOR THE AGED; HUMANS; MEDICATION THERAPY MANAGEMENT; NURSING HOMES; PRACTICE PATTERNS, PHYSICIANS'; UNITED STATES;

EID: 85010952326     PISSN: None     EISSN: 14712318     Source Type: Journal    
DOI: 10.1186/s12877-017-0428-1     Document Type: Review

References (40)

1. Nursing Home Reform Law, 42 U.S.C. §§1395i-3(a)-(h), 1396r(a)-(h) In. Edited by (Medicare and Medicaid r; 1987.
2. Kuehn BM. FDA warns antipsychotic drugs may be risky for elderly. JAMA. 2005;293(20):2462-2.
3. Levinson DR, Pattison BT, Walden DK. Medicare atypical antipsychotic drug claims for elderly nursing home residents: US department of health and human services, office of inspector general. 2011.
4. Bonner A. Improving dementia care and reducing unnecessary use of antipsychotic medications in nursing homes. Baltimore: Center for Medicare and Medicaid Services, ed Medicare Learning Network; 2013.
5. Services TCfMM. Partnership to Improve Dementia Care in Nursing Homes. Antipsychotic Drug use in Nursing Homes Trend Update. In.; 2014.
6. Ortman JM, Velkoff VA, Hogan H. An aging nation: the older population in the United States. Washington: US Census Bureau; 2014. p. 25-1140.
7. Health UDo, Services H. Long-term care services in the United States: 2013 Overview. 2013.
8. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing offlabel use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf. 2011;20(2):177-84.
9. AfHR Q. Off-label use of atypical antipsychotic drugs: a summary for clinicians and policymakers. 2007.
10. Chiu Y, Bero L, Hessol NA, Lexchin J, Harrington C. A literature review of clinical outcomes associated with antipsychotic medication use in North American nursing home residents. Health Policy. 2015;119(6):802-13.
11. Fossey J, Ballard C, Juszczak E, James I, Alder N, Jacoby R, Howard R. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. BMJ. 2006;332(7544):756-61.
12. Issues bulletin. The use of medicines in dementia care. London: IMS Health; 2009.
13. Banerjee S. The use of antipsychotic medication for people with dementia: Time for action. London: Department of Health; 2009.
14. Janus SI, van Manen JG, IJzerman MJ, Zuidema SU. Psychotropic drug prescriptions in Western European nursing homes. International psychogeriatrics. 2016;28(11):1-16.
15. Maher AR, Maglione M, Bagley S, Suttorp M, Hu J-H, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306(12):1359-69.
16. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225-35.
17. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934-43.
18. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W-65-94.
19. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, Initiative S. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Prev Med. 2007;45(4):247-51.
20. Bonner AF, Field TS, Lemay CA, Mazor KM, Andersen DA, Compher CJ, Tjia J, Gurwitz JH. Rationales that providers and family members cited for the use of antipsychotic medications in nursing home residents with dementia. J Am Geriatr Soc. 2015;63(2):302-8.
21. Bowblis JR, Crystal S, Intrator O, Lucas JA. Response to regulatory stringency: the case of antipsychotic medication use in nursing homes. Health Econ. 2012;21(8):977-93.
22. Briesacher BA, Limcangco MR, Simoni-Wastila L, Doshi JA, Levens SR, Shea DG, Stuart B. The quality of antipsychotic drug prescribing in nursing homes. Arch Intern Med. 2005;165(11):1280-5.
23. Briesacher BA, Tjia J, Field T, Peterson D, Gurwitz JH. Antipsychotic use among nursing home residents. JAMA. 2013;309(5):440-2.
24. Castle NG, Hanlon JT, Handler SM. Results of a longitudinal analysis of national data to examine relationships between organizational and market characteristics and changes in antipsychotic prescribing in US nursing homes from 1996 through 2006. American J Geriatric Pharmacotherapy. 2009;7(3):143-50.
25. Chen Y, Briesacher BA, Field TS, Tjia J, Lau DT, Gurwitz JH. Unexplained variation across US nursing homes in antipsychotic prescribing rates. Arch Intern Med. 2010;170(1):89-95.
26. Hughes CM, Lapane KL, Mor V. Influence of facility characteristics on use of antipsychotic medications in nursing homes. Med Care. 2000;38(12):1164-73.
27. Huybrechts KF, Rothman KJ, Brookhart MA, Silliman RA, Crystal S, Gerhard T, Schneeweiss S. Variation in antipsychotic treatment choice across US nursing homes. J Clin Psychopharmacol. 2012;32(1):11-7.
28. Kamble P, Chen H, Sherer J, Aparasu RR. Antipsychotic drug use among elderly nursing home residents in the United States. American J Geriatric Pharmacotherapy. 2008;6(4):187-97.
29. Kamble P, Chen H, Sherer JT, Aparasu RR. Use of antipsychotics among elderly nursing home residents with dementia in the US: an analysis of national survey data. Drugs Aging. 2009;26(6):483-92.
30. Kamble P, Sherer J, Chen H, Aparasu R. Off-label use of second-generation antipsychotic agents among elderly nursing home residents. Psychiatr Serv. 2010;61(2):130-6.
31. Lester P, Kohen I, Stefanacci RG, Feuerman M. Antipsychotic drug use since the FDA black box warning: survey of nursing home policies. J Am Med Dir Assoc. 2011;12(8):573-7.
32. Lucas JA, Chakravarty S, Bowblis JR, Gerhard T, Kalay E, Paek EK, Crystal S. Antipsychotic medication use in nursing homes: a proposed measure of quality. Int J Geriatr Psychiatry. 2014;29(10):1049-61.
33. Miller SC, Papandonatos G, Fennell M, Mor V. Facility and county effects on racial differences in nursing home quality indicators. Soc Sci Med. 2006;63(12):3046-59.
34. Pimentel CB, Donovan JL, Field TS, Gurwitz JH, Harrold LR, Kanaan AO, Lemay CA, Mazor KM, Tjia J, Briesacher BA. Use of atypical antipsychotics in nursing homes and pharmaceutical marketing. J Am Geriatr Soc. 2015;63(2):297-301.
35. Stevenson DG, Decker SL, Dwyer LL, Huskamp HA, Grabowski DC, Metzger ED, Mitchell SL. Antipsychotic and benzodiazepine use among nursing home residents: findings from the 2004 National Nursing Home Survey. Am J Geriatr Psychiatr. 2010;18(12):1078-92.
36. Svarstad BL, Mount JK, Bigelow W. Variations in the treatment culture of nursing homes and responses to regulations to reduce drug use. Psychiatr Serv. 2001;52(5):666-72.
37. Tjia J, Field T, Lemay C, Mazor K, Pandolfi M, Spenard A, Ho SY, Kanaan A, Donovan J, Gurwitz JH, et al. Antipsychotic use in nursing homes varies by psychiatric consultant. Med Care. 2014;52(3):267-71.
38. Konetzka RT, Brauner DJ, Shega J, Werner RM. The effects of public reporting on physical restraints and antipsychotic use in nursing home residents with severe cognitive impairment. J Am Geriatr Soc. 2014;62(3):454-61.
39. Zhang NJ. National Quality Measurement Systems for Assessment of Nursing Home Care. 2009.
40. Grabowski DC. A longitudinal study of Medicaid payment, private-pay price and nursing home quality. Int J Health Care Finance Econ. 2004;4(1):5-26.